Global Antiviral Drugs Market Report and Forecast 2024-2032

Global Antiviral Drugs Market Outlook

The global antiviral drugs market size attained a value of USD 55.17 billion in 2023 driven by rising prevalence of viral infections, coupled with the rising healthcare expenditure in the emerging economies. The market is anticipated to grow at a CAGR of 4.1% during the forecast period of 2024-2032 to attain a value of USD 79.21 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America Represents a Considerable Share of the Antiviral Drugs Industry

The antiviral drugs industry is driven by the rising prevalence of viral infections and the increasing research and development (R&D) of antiviral drugs. North America holds a considerable market share of this sector, which can be attributed to the presence of major companies in the region. The widespread access to standard medical services in the region is also surging the demand for antiviral drugs, which is bolstering the market growth. Moreover, the introduction of various favourable government initiatives in the region is driving the market for antiviral drugs. For instance, in July 2021, the United States government announced an investment of more than USD 3 billion in the American Rescue Plan to accelerate the discovery, development and manufacturing of antiviral medicines.

Meanwhile, the Asia Pacific region is expected to grow due to the robustly developing healthcare and the introduction of favourable government initiatives. With the increasing manufacturing capacity of the pharmaceuticals in India and China, the market is poised to witness rapid growth in the forecast period.

Antiviral Drugs: Market Segmentation

Antiviral drugs are medications that are used to treat viral diseases by either killing the virus present or inhibiting the virus from replicating and spreading. Antiviral drugs are typically used to treat specific viruses. Moreover, broad-spectrum antiviral drugs are effective against a wide range of viruses.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The major drug classes of antiviral drugs are:

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

Based on type, the market is bifurcated into:

• Branded
• Generic

The market can be broadly categorised on the basis of its applications into:

• HIV 
• Hepatitis
• Influenza
• Herpes
• Others

The EMR report looks into the regional markets of antiviral drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Challenges Associated with the Development of Antiviral Drugs to Hinder the Market Growth

The challenges associated with the development of antiviral drugs owing to mutations of viruses is hindering the market growth. Moreover, the development of antiviral drugs involves high investments, which is impeding the growth of the market. As the precise diagnosis of viral issues is difficult and the efficiency of antiviral drugs is limited to early treatment, the demand for antiviral drugs is reducing and obstructing the market growth.

As antiviral drugs have a narrow antiviral spectrum, their demand is reducing, which is negatively impacting the growth of the market. With the growing demand for alternative medicines such as naturopathy and homoeopathy, the market growth may witness a decline. The risk of toxic side effects from antiviral drugs is reducing their use and constraining the industry growth. The increasing ineffectiveness of antiviral drugs against latent viruses may impede the market growth in the forecast period.

Key Industry Players in the Global Antiviral Drugs Market

The report presents a detailed analysis of the following key players in the global antiviral drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Gilead Sciences, Inc.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc.
• AbbVie Inc.
• Merck and Co., Inc.
• Johnson and Johnson Services, Inc.
• Cipla Inc.
• Bristol-Myers Squibb Company
• Aurobindo Pharma Limited
• Dr. Reddy’s Laboratories Ltd.
• Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report